181 related articles for article (PubMed ID: 11012250)
1. CML vaccines as a paradigm of the specific immunotherapy of cancer.
Pinilla-Ibarz J; Cathcart K; Scheinberg DA
Blood Rev; 2000 Jun; 14(2):111-20. PubMed ID: 11012250
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia as an immunological target.
Lim SH; Coleman S
Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
[TBL] [Abstract][Full Text] [Related]
3. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
[TBL] [Abstract][Full Text] [Related]
4. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
5. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
8. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
Norbury LC; Clark RE; Christmas SE
Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
[TBL] [Abstract][Full Text] [Related]
9. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
[TBL] [Abstract][Full Text] [Related]
10. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
[TBL] [Abstract][Full Text] [Related]
12. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
Wagner WM; Ouyang Q; Pawelec G
Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.
Clark RE; Christmas SE
Leuk Lymphoma; 2001; 42(5):871-80. PubMed ID: 11697642
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
Schwartz J; Pinilla-Ibarz J; Yuan RR; Scheinberg DA
Semin Hematol; 2003 Jan; 40(1):87-96. PubMed ID: 12563615
[TBL] [Abstract][Full Text] [Related]
15. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.
Posthuma EF; van Bergen CA; Kester MG; de Paus RA; van Veelen PA; de Ru AH; Drijfhout JW; Lurvink EG; Willemze R; Falkenburg JH
Haematologica; 2004 Sep; 89(9):1062-71. PubMed ID: 15377467
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
20. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]